Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, Alves F.

Clin Infect Dis. 2019 Apr 24;68(9):1530-1538. doi: 10.1093/cid/ciy747.


Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC.

Front Cell Infect Microbiol. 2018 Jun 1;8:181. doi: 10.3389/fcimb.2018.00181. eCollection 2018.


Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.


Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG.

J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140. doi: 10.1093/jac/dkx283.


Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC.

Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0. Review.


Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip AE, Kiers KC, Rosing H, Schellens JHM, Beijnen JH, Dorlo TPC.

J Pharm Biomed Anal. 2017 Feb 20;135:160-166. doi: 10.1016/j.jpba.2016.12.012. Epub 2016 Dec 9.


Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Castro MD, Gomez MA, Kip AE, Cossio A, Ortiz E, Navas A, Dorlo TP, Saravia NG.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02198-16. doi: 10.1128/AAC.02198-16. Print 2017 Mar.


Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.

PLoS Negl Trop Dis. 2016 Sep 14;10(9):e0004880. doi: 10.1371/journal.pntd.0004880. eCollection 2016 Sep.


Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.

Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2081-9. doi: 10.1128/AAC.02976-15. Print 2016 Apr.


Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:57-62. doi: 10.1016/j.jchromb.2015.06.017. Epub 2015 Jun 24.


Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP.

Antimicrob Agents Chemother. 2015 Jan;59(1):1-14. doi: 10.1128/AAC.04298-14. Epub 2014 Nov 3. Review.

Supplemental Content

Support Center